HER2 Is Not a Predictive Biomarker of Benefit From Up-front Chemotherapy Plus Bevacizumab or Anti-EGFR, but Negative Prognostic Factor in pMMR/MSS RAS/BRAF Wild-Type mCRC By Ogkologos - September 29, 2025 295 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a large analysis of HER2 status in patients enrolled in 8 randomised clinical trials Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR Geriatric Assessment Intervention Reduces Patient-Reported Symptomatic Toxicities in Older Patients with... November 17, 2022 Selpercatinib Shows Durable Efficacy in RET-Altered Thyroid Cancer August 28, 2020 FDA Approves Selumetinib for Paediatric Patients 1 Year of Age and... September 25, 2025 5-Year-Old Boy Battling Cancer Receives Dream Come True, Sworn In As... March 24, 2021 Load more HOT NEWS Celebrating 75 years of NHS cancer care Exosomes May Help Tumors Evade Immune System Contraception and cancer – a look behind the headlines Pursuing precision medicine in a flagship lung cancer trial
